Determining the effect of a new truncated CecropinA-Magenin2 (CE-MA) hybrid peptide on the expression of multidrug-resistant (MDR) Mycobacterium tuberculosis efflux genes
Archives of Microbiology · 2025
DOI: 10.1007/s00203-025-04314-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Microbiology, 2025. Verfasst von Mozhgan Raigani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Drug Resistance, Multiple, Bacterial, Antitubercular Agents, Bacterial Proteins. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
A significant issue in treating bacterial infections is multidrug resistance (MDR) microbes. Drug efflux pumps that reduce cellular drug accumulation are frequently linked to drug resistance. In this study, we set out to determine the effects of CE-MA truncated peptide derivatives against MDR Mycobacterium tuberculosis. Following the assessment of the minimum inhibitory concentrations (MICs) of these peptides against MDR Mycobacterium tuberculosis, a Real-Time PCR was used to examine the expression of six drug efflux pump genes. Next, an MTT assay was performed to test the cytotoxicity of peptides against the A549 cell line. The outcomes demonstrated that CE-MA significantly upregulated gene expression of mmr, and Rv0876c (⩾ 4-fold) than untreated bacteria. Also, under CMt2 stress, significant overexpression of Rv0876c and drrA was seen. However, the results show that upregulation in CMt2-treated bacteria in comparison CE-MA treated bacteria is significantly less for genes tap (P 0.05) on changing the expression of genes drrC and pstB. Less than 10% of the A549 cell line was susceptible to the toxicity of CMt1 and CMt2 at their MICs range. Our results emphasize the significance of investigating novel peptide-based approaches to combat MDR Mycobacterium tuberculosis and point to these peptides as prospective candidates for additional research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
- Drug Design and Bioinformatics Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, 13198, Iran.
- Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
- Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, 1316943551, Iran.
- Department of Biotechnology, Faculty of Biotechnology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- Nervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.
Zitieren
APA
Raigani, M., Sardari, S., Vaziri, F., Ghajavand, H., Kargarpour Kamakoli, M., Majidian, M., Mazhari, M., & Madanchi, H. (2025). Determining the effect of a new truncated CecropinA-Magenin2 (CE-MA) hybrid peptide on the expression of multidrug-resistant (MDR) Mycobacterium tuberculosis efflux genes. Archives of Microbiology. https://doi.org/10.1007/s00203-025-04314-2
Vancouver
Raigani M, Sardari S, Vaziri F, Ghajavand H, Kargarpour Kamakoli M, Majidian M, et al. Determining the effect of a new truncated CecropinA-Magenin2 (CE-MA) hybrid peptide on the expression of multidrug-resistant (MDR) Mycobacterium tuberculosis efflux genes. Archives of Microbiology. 2025. doi:10.1007/s00203-025-04314-2
BibTeX
@article{Raigani2025,
author = {Raigani, Mozhgan and Sardari, Soroush and Vaziri, Farzam and Ghajavand, Hasan and Kargarpour Kamakoli, Mansour and Majidian, Mobina and Mazhari, Mahsa and Madanchi, Hamid},
title = {Determining the effect of a new truncated CecropinA-Magenin2 (CE-MA) hybrid peptide on the expression of multidrug-resistant (MDR) Mycobacterium tuberculosis efflux genes},
journal = {Archives of Microbiology},
year = {2025},
doi = {10.1007/s00203-025-04314-2}
}
EUVIMED